Published in Glaucoma

The Ultimate Guide to Interventional Glaucoma with the Glaukos Portfolio

This post is sponsored by Glaukos

Interventional glaucoma is a treatment approach for managing ocular hypertension and various stages of glaucoma. Join Drs. Shah, Ristvedt, Micheletti, Funke, and Yadgarov as they discuss the available treatment options and how this new approach is influencing glaucoma management.

The Ultimate Guide to Interventional Glaucoma with the Glaukos Portfolio

Glaucoma Overview

Glaucoma is a progressive disease characterized by the loss of retinal ganglion cells and changes in the neuroretinal rim tissue of the optic nerve, leading to narrowed visual fields and potential blindness.1

Prevalence

Glaucoma affects approximately 22 million eyes in the US. However, only about 13 million of these eyes have been diagnosed, and around 12 million are currently receiving treatment. Among those being treated, around 11.6 million are using eye drops. In contrast, only approximately 350,000 patients have undergone selective laser trabeculoplasty (SLT), and another 400,000 have received minimally invasive glaucoma surgery (MIGS). Additionally, about 1 in 5 cataract patients also have glaucoma, but only 350,000 are treated with MIGS (Figure 1).2,3
Figure 1. Prevalence of Glaucoma
Figure 1. Prevalence of Glaucoma2,3

Etiology

The exact process by which glaucoma develops remains unclear. Intraocular pressure (IOP) depends on the balance between aqueous humor production by the ciliary body and its drainage through the trabecular meshwork and uveoscleral pathway, as shown below.1
Aqueous humor production/drainage1
Elevated IOP can put stress on the eye's posterior structures, especially the lamina cribrosa and surrounding tissues. The optic nerve fibers exit the eye at the lamina cribrosa, which is its weakest point and can be compressed or deformed under high IOP, leading to axonal damage and disrupted transmission. This process contributes to optic nerve injury characteristic of glaucoma and the gradual loss of retinal ganglion cells.1
Glaucomatous optic neuropathy can happen even with normal IOP, possibly due to low cerebrospinal fluid pressure around the optic nerve, creating a significant pressure difference. Other factors include impaired microcirculation, changed immune responses, excitotoxicity, and oxidative stress. Primary degenerative processes in nerve tissues can cause neurodegeneration of retinal neurons and central visual pathway cells, increasing their risk of injury.1
Acute closure glaucoma (ACG) patients often experience drainage obstructions, whereas patients with open-angle glaucoma (OAG) exhibit greater resistance to outflow.1

Risk Factors

There are several risk factors to consider, including age, gender, myopia, migraines, pigmentary dispersion syndrome, pseudo-exfoliation syndrome, diabetes, and smoking.1 Additional risk factors include race and family history, as illustrated in Figure 2.4
Figure 2
Figure 2. Glaucoma Risk Factors1,4

Diagnosis

Several factors must be considered when diagnosing glaucoma. A high IOP, above 22 mmHg, generally indicates glaucoma, but not everyone with elevated IOP will develop the condition. Additionally, visual field changes often occur, especially progressive midperipheral changes that gradually move inward, resulting in central or peripheral islands of vision.1
Detecting glaucoma early is challenging because the appearance of healthy individuals varies.1 During ophthalmic examination, the superior and inferior neuroretinal rims of the optic nerve are typically the first to be affected.5
Glaucoma can be categorized into mild, moderate, and severe as shown in Table 1.5
Table 1
Table 1. Glaucoma Categories

The Traditional Glaucoma Treatment Algorithm

The treatment goal when managing glaucoma is to reduce IOP through medication, laser treatments, procedural pharmaceuticals, and other procedures to delay disease progression, maintain vision,1 and quality of life.1,7 The aim is a 20-50% reduction in IOP, but this is influenced by pre-treatment pressure levels associated with retinal damage, the severity of the damage, risk factors for progression, life expectancy, and treatment side effects.1
Call out 1
There are many first-line topical treatment options for patients. Ophthalmic drops include prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. Table 2 presents the mechanism of action and supplementary information for each drug.1,5
Table 2
Table 2. Glaucoma First-line Topical Treatments1,5

The Need for Change

The question we should ask ourselves as clinicians is: Why are we treating patients with drops as primary therapy? With the growing population and increasing life expectancy of glaucoma patients, utilizing drops as primary therapy is already posing a number of challenges.
There are several shortcomings associated with topical drop therapy, and although it sometimes offers an effective short-term treatment option, adherence to treatment is crucial.1
Factors such as cost, side effects, and failure to reach the target IOP influence adherence,5 and adherence declines with multiple medications or increased dosing frequency.9 Lower adherence to anti-glaucoma therapy results in higher IOPs, increased fluctuations in IOP, and consequently worsening of glaucomatous visual field defects.10
shah quote 1
Chronic use of topical medications can lead to a plateau effect, in which the medication's effectiveness is limited or even declines over time, necessitating increased dosing. About 40% to 75% of glaucoma patients use two or more medications, which leads to shorter-lasting benefits and higher health-related costs with each additional medication in a patient's glaucoma treatment plan.9
Higher rates of progression and blindness are associated with medications because they do not necessarily reduce IOP fluctuations, including both diurnal and nocturnal variability, which is why procedural intervention is often a better option.9 Based on this understanding, topical drops are best used as a bridge and supplementary therapy.6
Shah quote 2
The interventional glaucoma (IG) approach shifts from a reactive, medication-focused model to a more proactive, procedure-based strategy. Early, or first-line, proactive procedural intervention may shift the disease trajectory rather than just delaying further procedures and surgery. That is, earlier intervention can help slow disease progression, potentially delaying or preventing visual disability as shown below.9
Change in trajectory with earlier intervention9
IG approaches do not aim to completely eliminate medications, which can still be a crucial part of glaucoma treatment in many regions. Instead, they challenge the routine prescription of medications as the primary and often only response in managing glaucoma. Similarly, they do not exclude filtering surgery for suitable patients but advocate earlier interventions to potentially avoid it altogether.12 Topical medication can be used as a bridge or supplemental therapy.6
The IG protocol involves customized pathways tailored to different stages of glaucoma, from OHT to advanced disease. Treatment decisions are based on patient-centered factors, including experiences before, during, and after the procedure, as well as future treatment options.6
The urgency of lowering IOP also guides the treatment plan. Options are categorized by stage and include procedural pharmaceuticals, laser treatments, tissue-sparing and non-tissue-sparing MIGS, filtering surgery, and topical medications. This framework helps providers apply IG principles and enhance patient care.6


Expanding Portfolio of Treatment Options

Procedural Pharmaceuticals

Procedural pharmaceuticals, including travoprost and bimatroprost implants, deliver the drug continuously, lowering IOP, total dosage, and systemic exposure, thereby decreasing the risk of side effects.13 It reduces the need to remember to take medication and addresses compliance challenges.13
ristevdt quote 1
iDose® TR is a sustained-release intraocular implant with 3 primary components (iDose TR prescribing information)16:
  1. Scleral anchor for insertion and secure attachment to the inner scleral wall via the trabecular meshwork
  2. Titanium body serving as a drug reservoir
  3. Membrane designed to release travoprost gradually over a targeted duration, designed to last up to 3 years.
The implant is designed to remain fixed and stable, positioned parallel to the iris and away from the corneal endothelium (iDose TR prescribing information).16
Animation: iDose TR procedure
A phase 3 study assessed the efficacy and safety of iDose TR in patients with OHT and OAG. It involved two Phase 3, parallel-group, double-masked, randomized, prospective, sham-controlled trials comparing iDose TR to topical timolol (0.5%) BID. At 3 months, iDose TR met the primary efficacy endpoint of non-inferiority to topical timolol. At 12 months, 81% of iDose TR participants were completely free of IOP-lowering topical medications, with 23% initially on two or more medications before the trial.14
In a 36-month follow-up analysis of phase 3 trials, data showed that 70% of iDose TR subjects remained controlled on the same or fewer IOP-lowering medications at 36 months after a single dose, compared with 58% of timolol subjects. It also showed continued excellent tolerability and safety over the 36-month duration.17
Most common ocular adverse events (OAEs) included increased IOP, eye pain, iritis, ocular hyperemia, dry eye, reduced visual acuity, and visual field defects. Most OAEs were mild or moderate and resolved.16

Lasers

Laser procedures effectively lower the IOP and minimize the long-term costs associated with the use of multiple pressure-lowering medications.5 It is considered to be minimally invasive and has a reasonable safety profile.5
For refractory OAG, particularly in patients not responding to pharmacological therapy, laser trabeculoplasty should be considered. Argon laser trabeculoplasty (ALT) employs a blue-green continuous-wave laser (488 and 514 nm) to disrupt the TM. Selective laser trabeculoplasty (SLT) uses low-energy, brief-duration, large-spot pulses from a green, frequency-doubled laser to target melanin-containing cells while sparing the TM tissue. SLT has become popular due to its favorable safety profile, comparable IOP-lowering efficacy, and the ability for repeated treatments. Other types of laser trabeculoplasty include titanium-sapphire laser trabeculoplasty and pattern scanning trabeculoplasty.5
Animation: SLT
Laser peripheral iridotomy (LPI) and laser peripheral iridoplasty are most effective for patients with ACG. There are some differences between the two procedures. Laser peripheral iridotomy involves creating a hole in the peripheral iris and is often performed to eliminate pupillary block. In contrast, laser peripheral iridoplasty utilizes low-power laser burns to reduce appositional angle closure by shrinking the peripheral iris when laser iridotomy is ineffective.5
Combining both treatments is safe and effective for lowering the IOP in eyes with acute primary ACG that do not respond to medication. For eyes unresponsive to other treatments, cyclodestructive procedures that damage the ciliary body can lower IOP by decreasing aqueous humor production. These procedures are also useful for secondary glaucoma types, such as uveitic, traumatic, or neovascular glaucoma, but can be challenging to control and carry risks.5
In the following sections, we will discuss the different minimally invasive glaucoma surgery (MIGS) options.

MIGS: Trabecular Outflow Pathway
Trabecular Bypass Implant
The three anatomically designed trabecular bypass stents (iStent infinite®) are designed to optimize outflow while causing minimal disruption to natural anatomy by occupying only 3% of Schlemm’s canal, leaving 97% untouched. This, together with a patented multidirectional stent design, helps bypass resistance and restores natural outflow.18
ristvedt quote 3
In the prospective, multicenter, 12-month pivotal trial, patients with open-angle glaucoma who had failed prior surgical and medical therapy underwent standalone iStent infinite® implantation.19
  • 91.7% of patients in the failed prior surgery group reduced or maintained medication burden at 12 months19
  • 80.0% of patients in the failed prior surgery group had >20% IOP reduction19
  • 47.3% of patients in the failed prior surgery group had >30% IOP reduction19
Additionally, exceptional intraoperative and postoperative safety was shown among patients with two or more failed filtering surgeries. Only 4.9% of eyes needed secondary surgical intervention after iStent Infinite implantation over 12 months, despite multiple previous surgical failures. Additionally, there was no Hypotony, explant, cyclodialysis clefts, or device-related interventions.19
Animation: iStent Infinite® procedure
The iStent inject® W is indicated for use in conjunction with cataract surgery to lower IOP in adult patients with mild to moderate primary open-angle glaucoma.20 It creates two bypass pathways through the trabecular meshwork, which is the main resistance to aqueous outflow, allowing flow in multiple directions through Schlemm’s canal. It is among the smallest medical devices implanted in the human body.20 Glaukos trabecular micro-bypass stents are positioned two to three clock hours apart, designed to access multiple collector channels and flow arches spanning up to five to six clock hours. They may also help restore flow in dormant outflow channels.21
The iStent inject® W with Infinite Injector Technology (Figure 3) shares the same indication and mechanism of action as the iStent inject® W. The main difference is that it allows unlimited stent delivery attempts using an advanced injector.22
figure 3
Figure 3. iStent inject® W with Infinite Injector Technology
Ab-interno canaloplasty
Ab-interno canaloplasty targets the trabecular outflow pathway. It is not suitable for severe glaucoma but has comparable safety and efficacy to ab-externo canaloplasty5
Ab-interno trabeculotomy
Ab-interno trabeculotomy also targets the trabecular outflow pathway. This procedure and goniotomy procedures create direct communication between the anterior chamber, Schlemm's canal, and distal collector channels by disrupting or partially removing the TM5
Excisional goniotomy
Excisional goniotomy is performed using the iAccess Precision Blade® (Glaukos). Trabeculectomy and goniotomy can be performed concurrently. Due to the nature of the procedure, it creates a clean excision of the TM, which limits fibrosis and closure.5


MIGS: Subconjunctival Space

These surgeries redirect aqueous humor flow directly into the subconjunctival space. One of the issues with surgeries in this space is that it may lead to subconjunctival fibrosis. However, in surgeries such as a trabeculectomy, it may be prevented with intraoperative application of mitomycin-C.5

MIBS: Minimally Invasive Bleb Surgery

IOP decreases through the implantation of a device that creates a new pathway for eye fluid drainage, known as subconjunctival outflow. Bleb fibrosis is the most common cause of surgical failure, and the use of mitomycin-C may reduce its occurrence. MIBS may be safer than trabeculectomy and cause fewer follow-ups, but current evidence remains uncertain.23

MIGS: Suprachoroidal Space

These surgeries enhance uveoscleral outflow. The uveoscleral pathway is not limited by the pressure “floor” caused by episcleral venous pressure; therefore, diverting the aqueous humor into the suprachoroidal space could offer a greater IOP-lowering effect. However, long-term effectiveness may be restricted by fibroblast migration and growth, and studies on efficacy are needed.5

Traditional Surgical Treatment

Trabeculectomy involves creating a partial-thickness scleral flap and removing a segment of the trabecular meshwork to establish an alternative drainage pathway into the subconjunctival space. It has been considered the “Gold standard” glaucoma surgery for decades because it effectively controls intraocular pressure (IOP), especially aiming for the low teens to slow glaucoma progression.5
Glaucoma drainage devices (tube shunts) create a permanent sclerostomy to drain aqueous humor into the subconjunctival space. They serve as an alternative to trabeculectomy by reducing conjunctival scarring by diverting aqueous drainage to the equatorial region of the eye, away from the limbus, leading to the formation of a permanent bleb (plate tube).5
The main issue with traditional surgeries is their high complication rates. Potential complications from these procedures can include the formation of scar tissue, endophthalmitis, and conjunctival hemorrhage. Additionally, the effectiveness of these surgeries in lowering intraocular pressure (IOP) often decreases over time, leading to higher reoperation rates after 5 years. These unsuccessful surgeries and complications may require further postoperative intervention.5

What to do, when and why

The traditional reactive treatment of drops, laser, and filtering procedures has drawbacks that limit its suitability for a chronic, progressive, irreversible, and vision-threatening disease like glaucoma.9
micheltti quote 1
Below is an overview of the treatment protocols for OHT, mild, moderate, and severe glaucoma.
Animation: Treatment Protocols for Ocular Hypertension, Mild Glaucoma, Moderate Glaucoma, and Severe Glaucoma.
The IG consensus protocol assumes that the patient is previously undiagnosed and untreated, with no other significant comorbidities.6
The issue with monotherapy is that it uses single-mechanism, single-modality treatments, which often fail to achieve adequate IOP control, necessitating multi-mechanism and multi-modal approaches.11
The rationale to utilize procedures as primary therapy is that early IOP reduction and control of IOP fluctuations can prevent disease progression and thus a second surgery, improve patient satisfaction, and be cost-effective over time, thereby enhancing long-term outcomes.11
mich quote 2
The Multimodal/multi-mechanism approach utilizes multiple methods to lower IOP and combines treatments—medications, laser therapy, and procedure—early in the process, rather than sequentially, as in traditional practice, to maximize the available options.11
Multi-mechanism therapy targets various aspects of IOP regulation, including trabecular outflow, uveoscleral outflow, and aqueous suppression, utilizing medications, laser therapy, and surgical interventions.11 With a multidrug regimen, it is beneficial to choose drugs with complementary mechanisms of action to target multiple components of the IOP regulation pathway. Multiple procedures can be combined to enhance therapeutic effectiveness by targeting different mechanisms of IOP reduction, such as combining canaloplasty with trabeculotomy to lower both trabecular and post-trabecular outflow resistance. Together, a multi-mechanism approach can effectively target some or all of the factors that influence IOP, facilitating comprehensive IOP management.11
Multi-modal therapy combines different treatment modalities (e.g., medications and MIGS) concurrently rather than sequentially, providing significant and lasting IOP reduction while reducing medication burden.11
Micheletti et al. pointed out that the Collaborative Initial Glaucoma Treatment Study (CIGTS) showed that surgery effectively prevented visual field loss, but medical therapy was equally effective in mild to moderate glaucoma and less so in advanced cases, due to similar target IOP levels. However, the high medication burden and nonadherence suggest that such regimens may be less effective outside of clinical trials.11

The Argument for Standalone MIGS versus MIGS + Cataract Surgery

In the past, MIGS was combined with cataract surgery. However, it was not a lack of clinical efficacy but rather practical and regulatory issues that initially limited many MIGS procedures to cataract surgery. The issue with this approach is that linking glaucoma treatment to cataract surgery may unnecessarily limit patients' options to a narrow window.9
Cataract surgery leads to a modest reduction in intraocular pressure (IOP), with a decrease of less than 2 mm Hg, corresponding to a 16.5% reduction after 3 years. Evidence indicates that the reduction in IOP is more significant one year after cataract surgery, but over time, IOP tends to return to baseline levels.9
IG is a proactive approach as it advocates for earlier procedural intervention regardless of lens status. This approach seeks to lower and maintain IOP, delay or avoid high-risk surgery, and reduce the burden on patients by lowering their medication load.9
Standalone MIGS complements an interventional, proactive approach. It offers a crucial option for patients who need better solutions than ineffective drops and serves as an alternative to riskier filtering surgeries. More than 50 scientific studies have confirmed the safety and effectiveness of trabecular micro-bypass when used alone. These devices demonstrate comparable efficacy among themselves, and, specifically for iStent and iStent inject, they share similar overall and corneal endothelial safety profiles with cataract surgery alone.
With IG, individual patients achieve the lowest IOP possible without excessive risk and have the best chance of preventing disease progression from the start.11

IG Benefits the Patient, Practice, and HCP

IG is a patient-centric framework.6 There is some diminished quality of life (QOL) associated with eye drop usage,24 and early procedural intervention seeks to alleviate the negative quality of life impact associated with eye drop usage.6 Drop usage can lead to depression, anxiety, lower self-image, and reduced confidence in healthcare. Patients may feel they lack control over their disease, especially when it progresses.24
Interventional glaucoma prioritizing procedures over drops results in more consistent IOP control, better patient compliance, a lower medication burden, and a faster recovery time (Katz, 2024).12 It also avoids unwanted side effects of topical medications, such as ocular surface disease, hyperemia, hyperpigmentation of eyelids and iris, and systemic reactions that can result in death (Gallardo, 2024).24
funke quote 1
Medications tend to reach a plateau effect and may lose efficacy over time.24 Early procedural intervention aims to preserve vision more effectively, consistently, reliably, and comfortably.6 74% of patients with glaucoma who had been using drops for at least 6 months had ocular surface disease (OSD).25
Medications can also place a burden on caregivers and relatives, as ongoing treatment might be more demanding than the disease itself. Patients may experience difficulties with reading, driving, and mobility. There can also be financial and psychological implications for their caregivers and family members.24
For healthcare professionals and their practices, IG provides a practical framework or protocol that serves as a starting point.6 It leads to fewer intraoperative complications, easier follow-up care, and better tissue preservation in case of future surgery.12
IG incorporates patient education into the clinical flow, with staff members educating patients during pre-testing, while they wait to be seen, and after the exam. Taking the time to provide targeted education on disease processes and treatment options can reduce anxiety about the disease and enhance patient knowledge.
funke quote 2

Collaborative Care

The Importance of Education in Collaborative Care

The established consensus treatment protocol shapes patient care by guiding the next steps in education. It must be led by doctors to avoid confusion, since patients tend to trust their doctors to recommend what is best. Consequently, it is crucial to educate referring doctors so they can appropriately inform their patients. Many glaucoma specialists mainly receive referrals from optometrists, and since glaucoma is a progressive and hard-to-control disease, referrals are common. Patients visiting corporate and private optometry practices often make good candidates for SLT or procedural pharmaceuticals. Early procedural intervention aims to prevent the development of refractory glaucoma, which is difficult to treat.

Building a Referral Network

Collaborative care is essential when implementing IG in your practice. Building a referral network with local optometrists and ophthalmologists is crucial, though it can seem challenging at first. Some optometrists are only comfortable with sending referrals to doctors with whom they have a relationship and feel like there is a willingness to work with them. An effective strategy to build this relationship is hosting educational events. Make it easy for optometrists and other referring doctors to contact you, whether through follow-up conversations about patients or by offering simple ways to text you when needed. If you have optometrists on your staff, they can also help facilitate referrals.
You can also create practice-related marketing tools, such as handouts of the consensus protocol and basic information about your services. To further increase awareness, reach out to companies with a list of optometrists to educate them about your treatment options.
yad quote 2

Establishing Referral Protocols

Provide referral forms to referring doctors, including details like previous procedures, the highest recorded (max) IOP (Tmax), and current ophthalmic and systemic medications. This helps minimize redundant tests and allows providers to conduct further tests if needed. While referring doctors don't need to know every option the practice offers, they should be aware that options exist. Emphasize that early procedural intervention is crucial for preserving vision and maintaining a high quality of life. Early referrals educate patients about available treatments, helping them understand the procedures and make informed decisions about proceeding.

Best Practices

There are a few best practices for collaborative care based on our experience. For patients with mild to moderate glaucoma, perform SLT or procedural pharmaceuticals as the intervention and refer back to the optometrist for management. For patients with severe glaucoma, both the glaucoma specialist and optometrist should monitor for progression. This increases the number of pressure checks/contact with the patient, so there is a greater chance that progression is caught before it becomes an issue.

Key Takeaways

The main point is to invest in yourself and your patient. Take the time to refine your diagnostic skills, such as practicing good gonioscopy, understanding the evidence, and understanding the rationale behind various protocols, to enhance your communication with patients. It’s also essential to develop the ability to perform gonioscopy and procedures such as procedural pharmaceuticals and SLT, accurately.
Talking about lasers and procedures can be intimidating, but if you genuinely believe in what you're doing, your patients will respect that. They will see that you're doing it for their benefit, not for any other reason. When you present your case from the patient’s perspective and focus on their best interests, things tend to go very smoothly. The responsibility falls on us. We are physicians who have taken an oath to care for patients and help them lead the best lives possible. We do this through their eyes, by managing their disease. If we truly believe in this mission, we should assume the burden of care instead of passing it on to patients, which can be stressful, frightening, and fraught with side effects and risks.
As doctors, we're prepared to handle these challenges, and patients shouldn’t have to. IG represents a shift in the treatment of glaucoma, helping to preserve vision for patients.
PM-US-3431
The Faculty were compensated by Glaukos for their time.

iStent® Trabecular Micro-Bypass System United States

INDICATION FOR USE

The iStent Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication.

CONTRAINDICATIONS

The iStent ®is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS

Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent® is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details.

PRECAUTIONS

The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent® has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after washout of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.

ADVERSE EVENTS

The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of = 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.

CAUTION

Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.


iDose TR

DOSAGE AND ADMINISTRATION

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

CONTRAINDICATIONS

iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

WARNINGS AND PRECAUTIONS

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

ADVERSE REACTIONS

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

INDICATIONS AND USAGE

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.


The iStent infinite® Trabecular Micro-Bypass System Model iS3

INDICATION FOR USE

The iStent infinite® Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed.

CONTRAINDICATIONS

The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS

Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard.

MRI INFORMATION

The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

PRECAUTIONS

The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.

ADVERSE EVENTS

The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%).

CAUTION

Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.


iStent inject® W Trabecular Micro-Bypass System Model G2-W

INDICATION FOR USE

The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.

CONTRAINDICATIONS

The iStent inject W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS

Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI INFORMATION

The iStent inject W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

PRECAUTIONS

The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

ADVERSE EVENTS

Common postoperative adverse events reported in the iStent inject ® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

CAUTION

Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

  1. Saifi AI, Nagrale P, Ansari KK, Saifi I, Chaurasia S. Advancement in Understanding Glaucoma: A Comprehensive Review. Cureus. 2023;15(9):e46254. Published 2023 Sep 30. doi:10.7759/cureus.46254
  2. Marketscope
  3. Data on file, Glaukos Corporation.
  4. McMonnies CW. Glaucoma history and risk factors. J Optom. 2017;10(2):71-78. doi:10.1016/j.optom.2016.02.003
  5. Wagner IV, Stewart MW, Dorairaj SK. Updates on the Diagnosis and Management of Glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022;6(6):618-635. Published 2022 Nov 16. doi:10.1016/j.mayocpiqo.2022.09.007
  6. Funke CM, Ristvedt D, Yadgarov A, Micheletti JM. Interventional Glaucoma Consensus Treatment Protocol. Expert Review of Ophthalmology. 2025;20(2):79-87. doi:10.1080/17469899.2025.2465330
  7. Yadgarov A, Provencher L, Shafer B, Funke C. Adopting Interventional Glaucoma Via Sustained-Release Therapies: The Wide-Ranging Impact of Procedural Pharmaceuticals in Ophthalmology. Ophthalmol Ther. 2024;13(11):2825-2838. doi:10.1007/s40123-024-01041-7
  8. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598-606. doi:10.1016/j.ajo.2005.04.051
  9. Micheletti JM, Brink M, Brubaker JW, Ristvedt D, Sarkisian SR. Standalone interventional glaucoma: Evolution from the combination-cataract paradigm. Journal of Cataract & Refractive Surgery. 2024;50(12):1284-1290. doi:10.1097/j.jcrs.0000000000001537
  10. Tapply I, Broadway DC. Improving Adherence to Topical Medication in Patients with Glaucoma. Patient Prefer Adherence. 2021;15:1477-1489. Published 2021 Jul 2. doi:10.2147/PPA.S264926
  11. Micheletti JM, Shultz M, Singh IP, Samuelson TW. An emerging multi-mechanism and multi-modal approach in interventional glaucoma therapy. Ophthalmology and Therapy. 2024;14(1):13-22. doi:10.1007/s40123-024-01073-z
  12. Katz LJ, Myers J, Herndon L, Kresch Y, Hengerer F. Interventional glaucoma: Improving the patient-provider Educational Exchange. Clinical Ophthalmology. 2024;Volume 18:3365-3374. doi:10.2147/opth.s491287
  13. Fea AM, Vallino V, Cossu M, et al. Drug Delivery Systems for Glaucoma: A Narrative Review. Pharmaceuticals (Basel). 2024;17(9):1163. Published 2024 Sep 2. doi:10.3390/ph17091163
  14. Sarkisian SR, Ang RE, Lee AM, et al. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. Ophthalmol Ther. 2024;13(4):995-1014. doi:10.1007/s40123-024-00898-y
  15. Bacharach J, Doan LV, Stephens KG, et al. Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular Hypertension. Ophthalmol Ther. 2024;13(9):2357-2367. doi:10.1007/s40123-024-00992-1
  16. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.
  17. Sarkisian SR Jr et al. Poster presented at: American Glaucoma Society (AGS) Annual Meeting; February 26-March 2, 2025; Washington, DC.
  18. Inc. P. ISTENT INFINITE®: Glaucoma products. Glaukos. April 25, 2025. Accessed May 29, 2025. https://www.glaukos.com/glaucoma/products/istent-infinite/#.
  19. Sarkisian SR Jr, Grover DS, Gallardo MJ, et al. Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma. J Glaucoma. 2023;32(1):9-18. doi:10.1097/IJG.0000000000002141
  20. Inc. P. Istent inject® W surgery: Glaucoma products. Glaukos. May 31, 2024. Accessed May 29, 2025. https://www.glaukos.com/glaucoma/products/istent-inject-w/.
  21. Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results. Ophthalmology. 2019;126(6):811-821. doi:10.1016/j.ophtha.2019.03.006
  22. Inc. P. ISTENT INJECT® W with infinite Injector Technology. Glaukos. July 1, 2025. Accessed July 16, 2025. https://www.glaukos.com/glaucoma/products/istent-inject-w-with-infinite-injector-technology/.
  23. Ontario Health. Minimally Invasive Bleb Surgery for Glaucoma: A Health Technology Assessment. Ont Health Technol Assess Ser. 2024;24(1):1-151. Published 2024 Jan 11.
  24. Gallardo M, Smith O, Trubnik V, Reiss G. Interventional glaucoma and the patient perspective. Expert Review of Ophthalmology. 2024;19(5):311-318. doi:10.1080/17469899.2024.2382149
  25. Chanekar SN, Usgaonkar UP, Akarkar SO. Ocular surface disease in glaucoma patients on topical medications and its relation to duration of treatment and number of medications. Journal of Clinical Ophthalmology and Research. 2022;10(2):55-58. doi:10.4103/jcor.jcor_203_20
Manjool Shah, MD
About Manjool Shah, MD

As an ophthalmologist and member of the NYU Langone Eye Center, Manjool Shah, MD, uses conventional and microinvasive glaucoma surgery (MIGS) techniques to treat patients who have glaucoma. He also manages and treat other complex conditions in the front of the eye, including complex and dislocated cataracts, problems with intraocular lens implants, and issues affecting the iris and pupil.

At the NYU Langone Eye Center, he harnesses top-tier imaging and diagnostic tools to develop a care plan and monitor each patient’s journey.

When not caring for patients, he is dedicated to teaching residents and fellows through his work with multiple national societies as well as through his role as the program director for the NYU Langone Glaucoma Fellowship Program.

Manjool Shah, MD
Deborah Gess Ristvedt, DO
About Deborah Gess Ristvedt, DO

Dr. Ristvedt is a board-certified ophthalmologist who leads our Alexandria, MN location where she treats her patients with respect and compassion. She is skilled in cataract and minimally invasive glaucoma surgery and oculoplastics.

Deborah Gess Ristvedt, DO
Morgan Micheletti, MD
About Morgan Micheletti, MD

J. Morgan Micheletti, MD, FACS, is a board-certified ophthalmologist, partner, director of research, and fellowship director at Berkeley Eye Center. He has performed over 10,000 surgeries, specializing in cataract, vision-correction, microinvasive glaucoma, and complex anterior segment surgery. Dr. Micheletti serves as a medical advisor to over 20 companies, is the director of clinical strategy for Synopic, and is on the board of directors for the Society of Excellence in Eyecare (SEE). He is also a fellow of the World College of Refractive Surgery and Visual Sciences.

Morgan Micheletti, MD
Christine Funke, MD
About Christine Funke, MD

Christine Funke, MD, is a fellowship-trained glaucoma specialist who enjoys caring for a multitude of eye conditions, including glaucoma, visually significant cataracts, diabetes, dry eye, and routine eye care. She grew up in the western suburbs of Chicago and studied biology at the University of Notre Dame.

After her undergraduate education, she earned her medical degree at Rush Medical College and completed her residency in Cleveland, Ohio, at Case Western Reserve University. During her tenure at Case Western, Dr. Funke co-founded the University Eye Hospitals Alumni Association, was the representative to the Mid-Year Forum for the Women in Ophthalmology Society, spoke at numerous conferences, and was active on a myriad of research projects and publications.

She authored a chapter on alternative therapies for glaucoma treatment and has an interest in the effects of exercise and herbal therapy on eye pressure and vision. After completing her residency, she studied glaucoma at the prestigious University of Illinois Eye and Ear Infirmary. During her fellowship training, she enjoyed caring for patients with advanced, complex glaucoma.

Dr. Funke is an active member of The American Academy of Ophthalmology, The American Glaucoma Society, Women in Ophthalmology Society, Chicago Women in Ophthalmology group, and Chicago Glaucoma Society.

Christine Funke, MD
Arkadiy Yadgarov, MD
About Arkadiy Yadgarov, MD

Dr. Arkadiy Yadgarov is a Board Certified Ophthalmologist who graduated summa cum laude from Georgia Tech, and received his MD degree from The Medical College of Georgia in Augusta. His ophthalmology residency at the Institute of Ophthalmology and Visual Science of Rutgers University in New Jersey exposed him to a wide spectrum of complex eye diseases, challenging eye surgeries, and ocular trauma. He graduated with nationally ranked academic scores at the top of his class, and was honored with the Alfonse A. Cinotti, M.D. Award for Academic and Professional Excellence.

Dr. Yadgarov then completed his glaucoma fellowship at the prestigious New York Eye and Ear Infirmary. His surgical experience includes Baerveldt, Ahmed, and Molteno tube shunt implants, Xen Gel stent, trabeculectomy surgery, Kahook goniotomy, I-Stent insertion, and diode cyclophotocoagulation. He also has a special interest in advanced cataract surgery, including the use of iStent devices. He is a member of the American Academy of Ophthalmology and the American Glaucoma Society. Dr. Yadgarov was raised in the North Druid Hills area and is excited to be practicing back in his hometown of Atlanta.

Arkadiy Yadgarov, MD
Important Safety Information